Shukla Sanjay's Form 4 filing
aTYR PHARMA INCATYR · filed Dec 12, 2023
- Accession no.
- 0001209191-23-058377
- Filed
- Dec 12, 2023
- Trade date
- Dec 11-12, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $17.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shukla SanjayCIK 0001671026 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2023 | Common Stock | PPurchaseAcquired | +3,000 | $1.17 | +$3,510 | 94,173 | Direct | |
| Dec 12, 2023 | Common Stock | PPurchaseAcquired | +12,000 | $1.18F1 | +$14,160 | 106,173 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.175 to $1.18 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.